Market Overview

Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Revenue

Related NEOG
Earnings Scheduled For September 27, 2016
25 Stocks Which Rallied Four Days, Then Sold Off Yesterday
Neogen Corporation's (NEOG) CEO Jim Herbert on Q1 2017 Results - Earnings Call Transcript (Seeking Alpha)
Related VIVO
Sectors and Stocks To Watch If Hillary Clinton Is Elected
UPDATE: Meridian Bioscience Announces Investment in Oasis Diagnostics; Terms Not Disclosed

Below are the top small-cap diagnostic substances stocks on the NYSE and the NASDAQ in terms of revenue.

The trailing-twelve-month revenue at Neogen (NASDAQ: NEOG) is $179.10 million. Neogen had $61.33 million in total cash for the latest quarter.

The trailing-twelve-month revenue at Meridian Bioscience (NASDAQ: VIVO) is $169.11 million. Meridian Bioscience's PEG ratio is 1.37.

The trailing-twelve-month revenue at Abaxis (NASDAQ: ABAX) is $156.60 million. Abaxis's ROE for the same period is 7.97%.

The trailing-twelve-month revenue at Quidel (NASDAQ: QDEL) is $136.97 million. Quidel had $21.56 million in total cash for the latest quarter.

Posted-In: Diagnostic Substances Industry Highest Revenue small-capTrading Ideas


Related Articles (ABAX + NEOG)

View Comments and Join the Discussion!